Regeneron extends Ebola supply deal: what it means for Regeneron stock

Published on 10/27/2026 at 12:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Inmazeb deliveries continue through 2031 for the US government. Regeneron stock costs EUR 727.05 on October 27, 2026 before October 30 results.

Supply agreement and market context

Regeneron announced a USD 270 million Inmazeb supply agreement on October 26, 2026.
The company expects to deliver additional doses through 2031.
Regeneron stock traded at EUR 727.05 at 12:11 p.m. CET on October 27, 2026.

Regeneron, US75886F1075, Illustration mit AI erstellt.

Regeneron Pharmaceuticals (ISIN US75886F1075) extended its agreement with the US government on October 26, 2026, adding a USD 270 million supply commitment for its Ebola treatment Inmazeb. The Regeneron Pharmaceuticals release said additional doses are expected to reach the US government through 2031.

What does the contract mean?

The agreement expands a 2020 procurement arrangement with the Biomedical Advanced Research and Development Authority, or BARDA. Inmazeb combines three antibodies and was approved by the US Food and Drug Administration for infection caused by Orthoebolavirus zairense.

Regeneron said Inmazeb reduced mortality by 55 percent versus an active control in a clinical trial involving patients with low viral load. The treatment's safety and efficacy were established in the 681-patient PALM trial, according to the company release.

Results arrive October 30

The supply deal adds a commercial milestone to a week already centered on Regeneron's third-quarter report. A preview published by AlphaStreet says the company is scheduled to report before the market opens on October 30, 2026, with consensus estimates of USD 16.19 for earnings per share and USD 4.56 billion in revenue.

Market context after the announcement

Regeneron stock was trading at EUR 727.05 at Lang & Schwarz on October 27, 2026, at 12:11 p.m. CET. The Nasdaq-listed company had a market capitalization of USD 83.2 billion as of October 26, 2026, while its US share price was USD 807.67 in the finance quote snapshot.

The BARDA arrangement is not a substitute for clinical or commercial execution across Regeneron's larger portfolio. Its immediate value is the visibility of government demand through 2031 and the continued development of maftivimab in the PARTNERS trial.

The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.